Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 2

Conditions

Neoplasms 2Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × B3(Fv)-PE38KDEL recombinant immunotoxin × Lymphoid × Clear all
NCT00080535 2018-01-29

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 10 charts
DermatologicLymphoid

Lymphoma, Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00077922 2018-01-23

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
15 enrolled 10 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡